The Corona Remedies IPO, priced between ₹1,008–₹1,062 per share, saw robust demand, closing Day 3 with a 32× overall subscription.
The Non-Institutional Investor (NII) segment led the frenzy, oversubscribed 107×, while retail and qualified institutional buyers also showed strong interest.
Grey Market Premium (GMP) surged to around ₹30 per share, indicating high listing expectations. The IPO, valued at ₹655 crore through an offer-for-sale, reflects strong market confidence.
Investors are keenly watching the listing, but experts advise caution given the steep oversubscription and potential volatility post-listing.